399results about "Immunoglobulins against plants" patented technology

Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of an aryloxyalkanoate dioxygenase enzyme.

Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of a phosphinothricin-N-acetyl-transferase enzyme. The claimed antibodies and methods are particularly useful for identifying and quantitating the presence of phosphinothricin-N-acetyl-transferase expressed in trangenic plants.

The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding naturally-occurring allergen or portion thereof but having reduced side effects. Methods of treatment or of diagnosis of sensitivity to Japanese cedar pollens in an individual and therapeutic compositions, and multipeptide formulations comprising one or more peptides of the invention are also provided.

A pharmaceutical composition for treating allergy is described. The composition comprises as an active ingredient a recombinant polyclonal antibody or a mixture of different monoclonal antibodies capable of reacting with or binding to an allergen together with one or more pharmaceutically acceptable excipients. The composition may be used topically as a solution, dispersion, powder, or in the form of microspheres. The polyclonal antibody is preferably a recombinant polyclonal antibody produced by phage display technology. The pairing of specific immunoglobulin variable region light chain and heavy chain maintained from the original polyclonal immune response or selected by panning using the allergen in question is preferably maintained by bulk transfer of the pairs into an expression vector.

The present application discloses monoclonal antibody against cotinine and nicotine.

Methods and compositions for the screening and isolation of ligand-binding polypeptides, such as antibodies. In some aspects, methods of the invention enable the isolation of intact soluble antibodies comprising a constant domain. Screening methods that employ genetic packages such as bacteria and bacteriophages enable high through-put identification of ligand binding molecules.

Disclosed are nucleic acid molecules encoding polypeptides which are capable of conferring resistance against, and being triggered by, plant pathogens such as fungi (e.g. Phytophtora infestans and related isolates). Preferred nucleic acid molecules encode R1 from Solanum tuberosum, or a variety of homologs, naturally occurring or derivatives) thereof. Particular methods of activating resistance by using the R1 resistance gene are disclosed, which in certain cases lead to a hypersensitive response. Further aspects of the invention include specific primers, vectors, host cells, polypeptides, antibodies, aptamers, transgenic plants, methods of producing and employing these, and methods of influencing the resistance trait in a plant. Furthermore, screening methods for identifying and obtaining plant protective compounds are provided.